Is there a microangiopathic antiphospholipid syndrome?

被引：30

作者：

Asherson, Ronald A. ^{[1
]}

Pierangeli, Sylvia S.

Cervera, Ricard

机构：

[1] Univ Witwatersrand, Div Immunol, Sch Pathol, ZA-2196 Johannesburg, South Africa

[2] Univ Texas, Div Rheumatol, Galveston, TX 77555 USA

[3] Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona, Catolonia, Spain

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷 / 04期

关键词：

THROMBOTIC THROMBOCYTOPENIC PURPURA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; HEMOLYTIC-UREMIC SYNDROME; DISSEMINATED INTRAVASCULAR COAGULATION; SUBUNGUAL SPLINTER HEMORRHAGES; REFRACTORY HELLP-SYNDROME; CELL-ADHESION MOLECULE-1; VON-WILLEBRAND-FACTOR; ENDOTHELIAL-CELLS; TISSUE FACTOR;

D O I：

10.1136/ard.2006.067033

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Revealing the evolution of the term APS and its commonalities with other microangiopathic disorders.

引用

页码：429 / 432

页数：4

共 89 条

[51] Current understanding of disseminated intravascular coagulation [J].

Levi, M .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (05) :567-576

[52] Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-κB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway [J].

López-Pedrera, C ;

Buendía, P ;

Cuadrado, MJ ;

Siendones, E ;

Aguirre, MA ;

Barbarroja, N ;

Montiel-Duarte, C ;

Torres, A ;

Khamashta, M ;

Velasco, F .

ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :301-311

[53] Antiphospholipid syndrome: multiple mechanisms [J].

Mackworth-Young, CG .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 136 (03) :393-401

[54] Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus [J].

Martini, F ;

Farsi, A ;

Gori, AM ;

Boddi, M ;

Fedi, S ;

Domeneghetti, MP ;

Passaleva, A ;

Prisco, D ;

Abbate, R .

LUPUS, 1996, 5 (03) :206-211

[55] Occurence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand factor-cleaving protease [J].

Matsuda, J ;

Sanaka, T ;

Gohchi, K ;

Matsui, K ;

Uchida, S ;

Matsumoto, M ;

Fujimura, Y .

LUPUS, 2002, 11 (07) :463-464

[56]

McMahon LP, 1997, AUST NZ J OBSTET GYN, V37, P313

[57] Endothelial activation by aPL: A potential pathogenetic mechanism for the clinical manifestations of the syndrome [J].

Meroni, PL ;

Raschi, E ;

Camera, M ;

Testoni, C ;

Nicoletti, F ;

Tincani, A ;

Khamashta, MA ;

Balestrieri, G ;

Tremoli, E ;

Hess, DC .

JOURNAL OF AUTOIMMUNITY, 2000, 15 (02) :237-240

[58] Catastrophic antiphospholipid syndrome [J].

Merrill, JT ;

Asherson, RA .

NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2006, 2 (02) :81-89

[59] HEMOLYTIC-UREMIC SYNDROME WITH ANTICARDIOLIPIN ANTIBODIES REVEALING PARANEOPLASTIC SYSTEMIC SCLERODERMA [J].

MEYRIER, A ;

BECQUEMONT, L ;

WEILL, B ;

CALLARD, P ;

RAINFRAY, M .

NEPHRON, 1991, 59 (03) :493-496

[60] Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells [J].

Mitra, D ;

Jaffe, EA ;

Weksler, B ;

Hajjar, KA ;

Soderland, C ;

Laurence, J .

BLOOD, 1997, 89 (04) :1224-1234

← 1 2 3 4 5 6 7 8 9 →